Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments
搜索文档
 Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 Submission
 Newsfile· 2025-10-14 21:00
              Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 SubmissionOctober 14, 2025 9:00 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). T ...
 Adia Med Finalizing In-Network Access with the Nation's Largest Health Insurers Including Medicare, Medicaid, Humana, Cigna, and Florida Blue
 Newsfile· 2025-09-02 22:27
 公司业务进展 - 正在与Humana、Florida Blue、Cigna、Medicare和Medicaid等美国主要医疗保险提供商敲定网络内供应商地位 [2] - 已向Humana和Cigna提交申请并等待回应 与Florida Blue的流程已启动且供应商编号正在处理中 Medicare和Medicaid的接入正在积极进行中 [7] - 近期与PI Doctors Elite Community建立合作 连接全国超过4,000名人身伤害医师 [3]   战略发展目标 - 通过纳入保险网络使再生疗法更可及和可负担 扩大患者覆盖范围 [2][3] - 鼓励诊所所有者和医疗从业者授权Adia Med品牌或整合其再生疗法 寻求战略合作伙伴关系 [5] - 致力于通过创新再生解决方案变革医疗保健 包括脐带干细胞(UCB-SC)和自体造血干细胞移植(aHSCT)治疗 [6]   公司背景 - 在OTCQB市场公开交易 代码为ADIA 专注于革命性医疗保健和补充剂领域 [6] - 设立两个关键部门:提供优质有机补充剂的补充剂部门 以及建立专注于尖端干细胞治疗的诊所的医疗部门 [6] - 运营多个网站包括www.adianutrition.com、www.adiamed.com、www.adialabs.com等 [8]